Conclusion Plant and marine sources of n-3 PUFAs can modify serum leptin and adiponectin levels by increasing adiponectin and decreasing leptin levels in patients with type 2 diabetes .
Due to some limitations in this study , further studies are needed to reach a definitive conclusion about the effect of n-3 PUFAs on the levels of leptin and adiponectin in T2DM
Abstract Aim N-3 PUFAs can potentially influence levels of inflammatory and non-inflammatory adipokines .
Given the contradictory effects of n-3 PUFAs on serum levels of adipokines in type 2 diabetes , we conducted a systematic review and meta- analysis study of r and omized placebo-controlled clinical trials that examined the effects of n-3 PUFAs on serum levels of leptin and adiponectin in patients with type 2 diabetes .
Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes.
To investigate the relative role of the adiponectin and leptin in the insulin resistance ( IR ) and obesity we studied plasma levels of these adipocytokines in obese and insulin resistant postmenopausal ( PM ) females with type 2 diabetes ( DM2 ) during 6 months of Metformin therapy .  We recruited 26 PM women , between the ages of 50 and 67 ( 59,7+/-8,1 years ) . These women had a BMI of 36,6+/-1,8 kg/m2 . After baseline measurements Metformin therapy has been initiated ( 1700+/-2550 mg per day ) . Duration of therapy was 6 months . The results of investigations of adipocytokines after Metformin 6 months therapy shown that circulating adiponectin levels were significantly increased ( 19,1+/-6,0 vs. 16,1+/-3,9 ng/ml , p=0,008 ) together with significant reduction of BMI ( 35,9+/-1,9 vs. 36,6+/-1,8 kg/m2 , p=0,005 ) and IR ( 3,05+/-0,89 vs. 3,96+/-0,70 , p<0,001 ) . The magnitude of the change in adiponectin levels positively correlated with the magnitude of BMI reduction ( r=0,4784 , p=0,013 ) and IR reduction ( r=0,5779 , p=0,002 ) . Any significant correlation did not observed between changes of leptin levels and BMI , leptin levels and IR . In summary , our data suggest that hypoadiponectinemia in PM may be explained by only IR because the amelioration of whole-body insulin action by 6-month Metformin therapy leads to increase of plasma adiponectin levels ; leptin levels did not significantly change after 6-month Metformin therapy
Conclusion Plant and marine sources of n-3 PUFAs can modify serum leptin and adiponectin levels by increasing adiponectin and decreasing leptin levels in patients with type 2 diabetes .
Due to some limitations in this study , further studies are needed to reach a definitive conclusion about the effect of n-3 PUFAs on the levels of leptin and adiponectin in T2DM
Abstract Aim N-3 PUFAs can potentially influence levels of inflammatory and non-inflammatory adipokines .
Given the contradictory effects of n-3 PUFAs on serum levels of adipokines in type 2 diabetes , we conducted a systematic review and meta- analysis study of r and omized placebo-controlled clinical trials that examined the effects of n-3 PUFAs on serum levels of leptin and adiponectin in patients with type 2 diabetes .